CGTX Stock Price, Cognition Therapeutics, . Quote, Chart

Market Summary

USD1.90-0.03

Delayedas of 30 Apr 2024, 01:15 pm

-1.55%

CGTX Stock Price

View Fullscreen

CGTX RSI Chart

CGTX Valuation

Market Cap

75.3M

Price/Earnings (Trailing)

-2.92

Price/Sales (Trailing)

3.44

EV/EBITDA

-1.39

Price/Free Cashflow

-4.66

CGTX Price/Sales (Trailing)

CGTX Profitability

EBT Margin

-93.72%

Return on Equity

-105.37%

Return on Assets

-73.34%

Free Cashflow Yield

-21.48%

CGTX Fundamentals

CGTX Revenue

Revenue (TTM)

21.9M

Rev. Growth (Yr)

70.06%

Rev. Growth (Qtr)

-11.89%

CGTX Earnings

Earnings (TTM)

-25.8M

Earnings Growth (Yr)

-57.1%

Earnings Growth (Qtr)

-20.63%

Breaking Down CGTX Revenue

52 Week Range

1.203.49

(Low)(High)

Last 7 days

3.8%

Last 30 days

6.0%

Last 90 days

-17.9%

Trailing 12 Months

8.4%

How does CGTX drawdown profile look like?

CGTX Financial Health

Current Ratio

3.37

CGTX Investor Care

Shares Dilution (1Y)

33.21%

Diluted EPS (TTM)

-0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	19.7M	0	21.0M	21.9M
2022	18.7M	20.4M	23.3M	22.2M
2021	12.5M	14.2M	15.8M	17.4M
2020	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cognition Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	ricciardi lisa	bought	9,975	1.75	5,700	ceo & president
Feb 15, 2024	ricciardi lisa	acquired	-	-	75,000	ceo & president
Feb 15, 2024	doyle john brendan	acquired	-	-	20,000	chief financial officer
Feb 15, 2024	caggiano anthony	acquired	-	-	60,000	chief medical officer
Feb 03, 2024	caggiano anthony	sold (taxes)	-29,259	2.29	-12,777	chief medical officer
Feb 03, 2024	ricciardi lisa	sold (taxes)	-63,726	2.29	-27,828	ceo & president
Nov 08, 2023	kreis leslie w.	acquired	525,100	1.05	500,095	-
Nov 08, 2023	fletcher aaron g.l.	acquired	525,100	1.05	500,095	-
Jun 09, 2023	khattar jack a.	acquired	-	-	6,000	-
Jun 09, 2023	richstone ellen b	acquired	-	-	6,000	-

Which funds bought or sold CGTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-32,921	-	-%
Apr 24, 2024	Smith Anglin Financial, LLC	unchanged	-	-360	21,840	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	18,200	18,200	-%
Apr 11, 2024	Bangor Savings Bank	unchanged	-	-720	43,715	-%
Mar 11, 2024	VANGUARD GROUP INC	added	5.05	345,745	1,334,880	-%
Feb 26, 2024	Virtu Financial LLC	new	-	21,000	21,000	-%
Feb 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	added	720	219,000	242,000	-%
Feb 14, 2024	Baird Financial Group, Inc.	unchanged	-	9,181	41,427	-%
Feb 14, 2024	Royal Bank of Canada	added	765	-	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	37.76	73,392	168,720	-%

Are Funds Buying or Selling CGTX?

Are funds buying CGTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CGTX

No. of Funds

Unveiling Cognition Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	hirschman orin	4.8%	1,448,270	SC 13G/A
Jan 19, 2024	pathstone family office, llc	7.53%	2,205,377	SC 13G
Nov 13, 2023	bios memory spv i, lp	4.6%	1,424,014	SC 13D/A
Feb 15, 2023	hirschman orin	7.0%	2,037,853	SC 13G/A
Dec 05, 2022	bios memory spv i, lp	5.9%	1,424,014	SC 13D/A
Nov 18, 2022	hirschman orin	7.0%	2,037,853	SC 13G

Recent SEC filings of Cognition Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	4	Insider Trading
Mar 13, 2024	8-K	Current Report
Mar 13, 2024	424B5	Prospectus Filed
Mar 11, 2024	424B5	Prospectus Filed

Peers (Alternatives to Cognition Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Cognition Therapeutics, Inc. News

Latest updates

Cognition Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-11.9%	6,770,000	7,684,000	3,426,000	3,981,000	5,947,000	6,385,000	5,904,000	5,072,000	3,037,000	4,646,000	4,692,000	3,942,000	3,192,000
Operating Expenses	3.0%	15,189,000	14,745,000	8,973,000	9,300,000	12,625,000	12,213,000	9,413,000	11,808,000	5,223,000	5,984,000	5,583,000	-	4,461,000
S&GA Expenses	16.7%	3,589,000	3,076,000	3,543,000	2,860,000	4,357,000	3,115,000	2,895,000	6,235,000	1,548,000	1,090,000	1,153,000	-	1,062,000
R&D Expenses	-0.6%	11,600,000	11,669,000	5,430,000	6,440,000	8,268,000	9,098,000	6,518,000	5,573,000	3,675,000	4,894,000	4,430,000	-	3,399,000
EBITDA Margin	3.8%	-0.93	-0.97	-0.87	-0.49	-0.46	-0.53	-	-	-	-	-	-	-
Interest Expenses	-350.0%	-9,000	-2,000	-10,000	-10,000	-2,000	-7,000	-9,000	1,000	-	-357,000	-537,000	-	-506,000
Income Taxes	-	-	-	-	-	-	-125,000	125,000	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-6,172,000	-	-	-5,877,000	-3,713,000	-	-	-1,490,000	223,000	-	-
EBT Margin	3.8%	-0.94	-0.97	-0.87	-0.49	-0.47	-0.53	-	-	-	-	-	-	-
Net Income	-20.6%	-8,141,000	-6,749,000	-6,172,000	-5,182,000	-6,625,000	-5,752,000	-3,838,000	-7,339,000	-3,110,000	-1,490,000	223,000	-1,868,000	-1,791,000
Net Income Margin	-8.7%	-1.18	-1.09	-1.20	-0.96	-1.01	-0.98	-0.85	-0.67	-0.40	-0.35	-0.41	-0.72	-
Free Cashflow	-30.0%	-5,486,000	-4,219,000	-2,746,000	-10,194,000	-27,000	-5,361,000	-3,122,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-9.3%	35.00	39.00	44.00	46.00	50.00	54.00	53.00	59.00	59.00	13.00	7.00
Current Assets	-5.0%	34.00	36.00	42.00	43.00	48.00	51.00	51.00	56.00	59.00	10.00	7.00
Cash Equivalents	-9.2%	30.00	33.00	37.00	39.00	42.00	47.00	46.00	52.00	55.00	8.00	5.00
Net PPE	1.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	8.6%	11.00	10.00	10.00	10.00	10.00	14.00	9.00	10.00	8.00	15.00	20.00
Current Liabilities	23.6%	10.00	8.00	8.00	7.00	8.00	12.00	7.00	8.00	8.00	4.00	3.00
Shareholder's Equity	-15.4%	24.00	29.00	34.00	36.00	40.00	39.00	44.00	49.00	51.00	-	-
Retained Earnings	-6.1%	-141	-133	-126	-121	-115	-110	-103	-97.84	-94.00	-86.66	-68.22
Additional Paid-In Capital	2.3%	166	162	161	158	156	150	148	147	145	0.00	0.00
Shares Outstanding	5.7%	32.00	30.00	30.00	29.00	29.00	23.00	23.00	22.00	22.00	-	1.00
Float	-	-	-	43.00	-	-	-	38.00	-	81.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-31.1%	-5,456	-4,161	-3,696	-2,705	-10,184	-4.00	-5,357	-2,988	101	-2,050	-910	-772	-	-
Share Based Compensation	0%	1,071	1,071	1,025	1,187	902	777	892	1,001	4,919	72.00	94.00	98.00	-	-
Cashflow From Investing	48.3%	-30.00	-58.00	-18.00	-41.00	-10.00	-23.00	-4.00	-134	-	-	-	-	-	-
Cashflow From Financing	81400.0%	2,439	-3.00	2,095	-10.00	5,142	869	-374	-91.00	46,361	-961	-1,155	8,956	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CGTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Research and development	$ 37,196	$ 30,324
General and administrative	13,528	13,227
Total operating expenses	50,724	43,551
Loss from operations	(50,724)	(43,551)
Other income (expense):
Grant income	24,805	22,217
Other income (expense), net	158	(35)
Interest expense	(27)	(28)
Total other income, net	24,936	22,154
Net Loss	(25,788)	(21,397)
Unrealized gain (loss) on foreign currency translation	4	(1)
Total comprehensive loss	$ (25,784)	$ (21,398)
Net loss per share, basic (in dollars per share)	$ (0.86)	$ (0.91)
Net loss per share, diluted (in dollars per share)	$ (0.86)	$ (0.91)
Weighted-average common shares outstanding, basic (in shares)	30,029,087	23,640,199
Weighted-average common shares outstanding, diluted (in shares)	30,029,087	23,640,199

CGTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 29,922	$ 41,562
Grant receivables	1,281	3,672
Prepaid expenses and other current assets	3,019	2,413
Total current assets	34,222	47,647
Property and equipment, net	284	233
Right-of-use assets, operating leases	657	813
Other assets		1,732
Total assets	35,163	50,425
Current liabilities:
Accounts payable	3,695	3,216
Accrued expenses	4,055	2,094
Deferred grant income, current	1,701	1,702
Operating lease liabilities, current	174	149
Other current liabilities	544	634
Total current liabilities	10,169	7,795
Operating lease liabilities, noncurrent	520	695
Deferred grant income and other liabilities, noncurrent	0	1,686
Total liabilities	10,689	10,176
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.001 par value, 250,000,000 shares authorized; 32,165,478 and 28,991,548 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	32	29
Additional paid-in capital	165,826	155,820
Accumulated deficit	(141,189)	(115,401)
Accumulated other comprehensive loss	(195)	(199)
Total stockholders' equity	24,474	40,249
Total liabilities and stockholders' equity	$ 35,163	$ 50,425

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CEO	Ms. Lisa Ricciardi
WEBSITE	cogrx.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Cognition Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cognition Therapeutics, Inc.? What does CGTX stand for in stocks?

CGTX is the stock ticker symbol of Cognition Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cognition Therapeutics, Inc. (CGTX)?

As of Mon Apr 29 2024, market cap of Cognition Therapeutics, Inc. is 75.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGTX stock?

You can check CGTX's fair value in chart for subscribers.

What is the fair value of CGTX stock?

You can check CGTX's fair value in chart for subscribers. The fair value of Cognition Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cognition Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cognition Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGTX is over valued or under valued. Whether Cognition Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cognition Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGTX.

What is Cognition Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, CGTX's PE ratio (Price to Earnings) is -2.92 and Price to Sales (PS) ratio is 3.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGTX PE ratio will change depending on the future growth rate expectations of investors.